Identification of four distinct neutralizing epitopes on bluetongue virus serotype 10 using neutralizing monoclonal antibodies and neutralization-escape variants

Virology ◽  
1990 ◽  
Vol 176 (2) ◽  
pp. 658-661 ◽  
Author(s):  
Hans W. Heidner ◽  
Paul V. Rossitto ◽  
N.James MacLachlan
Keyword(s):  
Monoclonal Antibodies ◽  
Bluetongue Virus ◽  
Virus Serotype ◽  
Neutralizing Epitopes

scholarly journals Development of Neutralizing Monoclonal Antibodies for Oncogenic Human Papillomavirus Types 31, 33, 45, 52, and 58

2014 ◽  
Vol 21 (4) ◽  
pp. 587-593 ◽  
Author(s):  
Martha J. Brown ◽  
Hanna Seitz ◽  
Victoria Towne ◽  
Martin Müller ◽  
Adam C. Finnefrock
Keyword(s):  
Monoclonal Antibodies ◽  
Human Papillomavirus ◽  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Cervical Cancers ◽  
Hpv Types ◽  
Oncogenic Hpv ◽  
Neutralizing Epitopes ◽  
Selection Of

ABSTRACTHuman papillomavirus (HPV) is the etiological agent for all cervical cancers, a significant number of other anogenital cancers, and a growing number of head and neck cancers. Two licensed vaccines offer protection against the most prevalent oncogenic types, 16 and 18, responsible for approximately 70% of cervical cancer cases worldwide and one of these also offers protection against types 6 and 11, responsible for 90% of genital warts. The vaccines are comprised of recombinantly expressed major capsid proteins that self-assemble into virus-like particles (VLPs) and prevent infection by eliciting neutralizing antibodies. Adding the other frequently identified oncogenic types 31, 33, 45, 52, and 58 to a vaccine would increase the coverage against HPV-induced cancers to approximately 90%. We describe the generation and characterization of panels of monoclonal antibodies to these five additional oncogenic HPV types, and the selection of antibody pairs that were high affinity and type specific and recognized conformation-dependent neutralizing epitopes. Such characteristics make these antibodies useful tools for monitoring the production and potency of a prototype vaccine as well as monitoring vaccine-induced immune responses in the clinic.

Expression of a full-length nonstructural protein NS1 of bluetongue virus serotype 17 in Escherichia coli

1991 ◽  
Vol 180 (2) ◽  
pp. 994-1001 ◽  
Author(s):  
Xiao-Song He ◽  
Lin-Fa Wang ◽  
Roy H. Doi ◽  
Maurecio Maia ◽  
Bennie I. Osburn ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Bluetongue Virus ◽  
Nonstructural Protein ◽  
Full Length ◽  
Virus Serotype

scholarly journals Sustained high-throughput polymerase chain reaction diagnostics during the European epidemic of Bluetongue virus serotype 8

2012 ◽  
Vol 24 (3) ◽  
pp. 469-478 ◽  
Author(s):  
Piet A. van Rijn ◽  
René G. Heutink ◽  
Jan Boonstra ◽  
Hans A. Kramps ◽  
René G. P. van Gennip
Keyword(s):  
Polymerase Chain Reaction ◽  
High Throughput ◽  
Bluetongue Virus ◽  
Chain Reaction ◽  
Virus Serotype ◽  
Polymerase Chain

scholarly journals Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle

Vaccine ◽  
2014 ◽  
Vol 32 (49) ◽  
pp. 6614-6621 ◽  
Author(s):  
Jenna Anderson ◽  
Sara Hägglund ◽  
Emmanuel Bréard ◽  
Mickaël Riou ◽  
Siamak Zohari ◽  
...  
Keyword(s):  
Bluetongue Virus ◽  
Subunit Vaccine ◽  
Virus Serotype

scholarly journals Bluetongue Virus Serotype 8 Reemergence in Germany, 2007 and 2008

2008 ◽  
Vol 14 (9) ◽  
pp. 1421-1423 ◽  
Author(s):  
Bernd Hoffmann ◽  
Michael Saßerath ◽  
Sabine Thalheim ◽  
Claudia Bunzenthal ◽  
Günter Strebelow ◽  
...  
Keyword(s):  
Bluetongue Virus ◽  
Virus Serotype

A side effect of decreased fertility associated with vaccination against bluetongue virus serotype 8 in Holstein dairy cows

2011 ◽  
Vol 101 (1-2) ◽  
pp. 42-50 ◽  
Author(s):  
Simon Nusinovici ◽  
Henri Seegers ◽  
Alain Joly ◽  
François Beaudeau ◽  
Christine Fourichon
Keyword(s):  
Dairy Cows ◽  
Side Effect ◽  
Bluetongue Virus ◽  
Virus Serotype ◽  
Holstein Dairy Cows
Sign in / Sign up

Export Citation Format

Share Document